期刊文献+

澳大利亚“Sanofi-Aventis”公司案若干法律问题探讨 被引量:1

Issues on Australian “Sanofi-Aventis” Company Case
下载PDF
导出
摘要 关于药品说明书的著作权保护问题,我国理论界与实务界争论已久。药品说明书的独创性和合理使用问题,在澳大利亚司法实践中同样引起争议。有必要评介2011年澳大利亚Sanofi-Aventis公司案关于药品说明书独创性、默示许可方面的判决,分析Sanofi-Aventis公司案之得失,探索我国药品说明书著作权保护的合理路径。 The issues such as whether the product information of medicine is original and therefore should be protected by the Copyright Law has been discussed for a long time both in the practical and theoretical fields in China. It is necessary to analyze the disputes in the 2011 Australia "Sanofi-Aventis "' Company Case, review the judgement on the originality and implied license of the case, and search for the reasonable approach to the copyright protection of the product information of medicine.
作者 赵力
出处 《西安电子科技大学学报(社会科学版)》 CSSCI 2013年第2期117-123,共7页 Journal of Xidian University:Social Science Edition
基金 教育部人文社科基地重大课题"二十一世纪国际知识产权制度发展中的若干重大法律问题研究"(07JJD820163)子课题之三"国际知识产权制度与保护公共健康的若干法律问题"的部分成果
关键词 药品说明书 独创性 著作权 Information of medicine product Originality Copyright
  • 相关文献

参考文献12

二级参考文献25

  • 1黄正南.两个总体均数和两个总体率等价或差别有实际意义的统计推断[J].数理医药学杂志,1993,6(1):25-28. 被引量:5
  • 2梁云,邵蓉.美国仿制药管理的法制历程及其对我国的启示[J].食品与药品,2006,8(09A):67-69. 被引量:3
  • 3国务院新闻办公室.中国的药品安全监管状况[EB/OL].(2008-07-18)[2009-03-01].http://www.sfda.gov.cn/WS01/CL0051/31372.htm1.
  • 4袁曙宏,张敬礼.百年FDA-美国药品监管法律框架[M].北京:中国医药科技出版社,2007.
  • 5王建英.美国药品申垠与法姆管理[M].北京:中国医药科技出版社,2005:195-197.
  • 6US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: waiver of in vivo bioavailability and bioe- quivalence studies for immediate-release solid products, based on a biopharmaceutics classification system [EB/OL]. (2007-12- 17)[2010-01-12]. http: //www. fda. gov/cder/guidance/3618fnl. htm.
  • 7WHO. WHO expert committee on specifications for harmaceutical preparations: fortieth report; Annex 8: Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms [EB/OL]. (2008-12-15 ) [2010-01 - 12 ]. http : //whqlibdoc. who. int/trs/ WHO TRS 937 eng. pdf.
  • 8European Medicines Agency. Committee for proprietary edicinal products. Note for guidance on the investigation of bioequivalence [EB/OL]. (2008-07-24)[2010-01-12]. http: //www. emea. europa, eu/pdfs/human/qwp/140198enfin, pdf.
  • 9International Conference on Harmonisation. ICH harmonised tripar tite guideline: pharmaceutical development Q8 (R2) [EB/OL] (2008-07-24) [2010-03-19]. http: //www. ich. org/LOB/media/MEDIA4986, pdf.
  • 10US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Abbreviated new drug applications (ANDA) : generics [EB/OL] (2009-11-24) [2010-01-15]. http ://www. fda. gov/cder/ogd/.

共引文献52

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部